Complement activation via the alternative pathway in a patient with insulin-dependent diabetes mellitus.
A 41-year old male with insulin-dependent diabetes mellitus previously unsuccessfully treated with a controlled diet and glibenclamide, and subsequently with increasing insulin doses (5 and 20 IU/day) experienced polyuria, glycosuria and loss of weight. On admittance to hospital serum C3 concentrations were found to be depressed. The insulin dose was further increased to 30 IU/day and the patient was also treated with 20 mg nafamostat mesylate given intravenously twice daily for 6 days. On completion of nafamostat mesylate treatment serum C3 concentrations were increased but after 17 days they started to decrease again.
Okada
S
S
Third Department of Medicine, Okayama University Medical School, Japan.
Ichiki
K
K
Tanokuchi
S
S
Ishii
K
K
Hamada
H
H
Yamamoto
H
H
Ota
Z
Z
D000328:Adult; D001550:Benzamidines; D001786:Blood Glucose / Q000032:analysis; D003167:Complement Activation / Q000187:drug effects; D003176:Complement C3 / Q000032:analysis / Q000172:deficiency; D003170:Complement Pathway, Alternative; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male
D001550:Benzamidines; D001786:Blood Glucose; D003176:Complement C3; D006146:Guanidines; C032855:nafamostat